{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.1","upperLimit":"67.8","value":"64.0"},{"groupId":"OG001","lowerLimit":"48.6","upperLimit":"56.6","value":"52.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"628"},{"groupId":"OG001","value":"625"}],"units":"Participants"}],"description":"Participants achieved disease control if they had a best overall response of PR, CR or stable disease (SD). According to RECIST v1.1, PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter; CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \\<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels (if tumor markers were initially above the ULN). SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started. The percentage of participants who achieved disease control=(number of participants with CR, PR, or SD)/(number of participants assessed)\\*100.","dispersionType":"95% Confidence Interval","groups":[{"description":"On Day 1 of each 21-day cycle, participants received ramucirumab DP followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\n* Ramucirumab DP: 10 mg/kg administered intravenously.\n* Docetaxel: 75 mg/m\\^2 (60 mg/m\\^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously.","id":"OG000","title":"Ramucirumab and Docetaxel"},{"description":"On Day 1 of each 21-day cycle, participants received placebo followed by docetaxel. Treatment continued until disease progression, unacceptable toxicity, or other withdrawal criteria were met.\n\n* Placebo (matching Ramucirumab DP): 10 mg/kg administered intravenously.\n* Docetaxel: 75 mg/m\\^2 (60 mg/m\\^2 for the countries of Korea and Taiwan only, with protocol amendment dated 22 May 2012) administered intravenously.","id":"OG001","title":"Placebo and Docetaxel"}],"paramType":"NUMBER","populationDescription":"ITT population: All randomized participants grouped according to their assigned treatment at randomization.","reportingStatus":"POSTED","timeFrame":"Baseline to measured PD (up to 29 months)","title":"Percentage of Participants Achieving Disease Control (Disease Control Rate)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}